Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | CFD | P00746 | 1/20 | 0.51 |
| ▸ | SENP1 | Q9P0U3 | 4/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1854934 | 0.93 | EPHX2 (0.49) | EPHX2NR1H4CFDSENP1ERN1 | |
| SCHEMBL1851264 | 0.91 | LSS (0.48) | EPHX2NR1H4PPARGTRPV1HDAC1 | |
| SCHEMBL1855554 | 0.90 | EPHX2 (0.45) | EPHX2NR1H4CFDSENP1ERN1 | |
| SCHEMBL1857174 | 0.86 | NPC1 (0.49) | PPARGTRPV1POLBHDAC3HDAC1 | |
| SCHEMBL1851475 | 0.85 | MAPK14 (0.48) | EPHX2PPARGTRPV1TMEM97SIGMAR1 | |
| SCHEMBL1858311 | 0.83 | MLYCD (0.50) | TRPV1TMEM97SIGMAR1 | |
| SCHEMBL1856241 | 0.82 | TRPV1 (0.42) | EPHX2NR1H4SENP1PPARGTRPV1 | |
| SCHEMBL4325004 | 0.82 | AKR1C4 (0.40) | EPHX2NR1H4SENP1TRPV1POLB | |
| SCHEMBL1853060 | 0.82 | TMEM97 (0.49) | LTB4R2HDAC1HDAC2TMEM97SIGMAR1 | |
| SCHEMBL1855680 | 0.82 | TMEM97 (0.49) | LTB4R2HDAC1HDAC2TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470102-B1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | MERCK SERONO SA (CH) | 2011-05-25 | — | — | EP | claimed |
| EP-1732534-B1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | SERONO LAB (CH) | 2008-07-23 | — | — | EP | claimed |
| US-20070185118-A1 | Use of methylene amide derivatives in cardiovascular disorders | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | claimed |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | APPLIED RESEARCH SYSTEMS ARS (NL) | 2005-06-09 | — | — | US | claimed |
| EP-1470102-B1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | MERCK SERONO SA (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-7592477-B2 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) | LABORATOIRES SERONO SA (CH) | 2009-09-22 | — | — | US | disclosed |
| EP-1732534-B1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | SERONO LAB (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-20070185118-A1 | Use of methylene amide derivatives in cardiovascular disorders | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | disclosed |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | APPLIED RESEARCH SYSTEMS ARS (NL) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185118-A1 | Use of methylene amide derivatives in cardiovascular disorders | TNNI3, TNNT2, ADM2 | EPHX2 495/4885NR1H4 510/4885CFD 1222/4885 |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | PTPRS, PTPA, PTPMT1 | EPHX2 2771/4885NR1H4 1543/4885CFD 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.